Barbara JarzÄb

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2304299/publications.pdf

Version: 2024-02-01

211 papers	17,038 citations	30070 54 h-index	15266 126 g-index

220 all docs	220 docs citations	220 times ranked	14835 citing authors

#	Article	IF	Citations
1	European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology, 2006, 154, 787-803.	3.7	1,804
2	Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. Journal of Clinical Oncology, 2012, 30, 134-141.	1.6	1,295
3	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet, The, 2014, 384, 319-328.	13.7	1,295
4	Cabozantinib in Progressive Medullary Thyroid Cancer. Journal of Clinical Oncology, 2013, 31, 3639-3646.	1.6	989
5	Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7269-7274.	7.1	792
6	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. JAMA - Journal of the American Medical Association, 2013, 309, 1493.	7.4	775
7	Combination Chemotherapy in Advanced Adrenocortical Carcinoma. New England Journal of Medicine, 2012, 366, 2189-2197.	27.0	692
8	Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer. Journal of Clinical Oncology, 2015, 33, 42-50.	1.6	448
9	Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer. Journal of Clinical Oncology, 2009, 27, 3794-3801.	1.6	337
10	Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1502-1505.	7.1	311
11	Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. European Journal of Endocrinology, 2004, 150, 105-112.	3.7	295
12	Gene Expression Profile of Papillary Thyroid Cancer: Sources of Variability and Diagnostic Implications. Cancer Research, 2005, 65, 1587-1597.	0.9	238
13	A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clinical Cancer Research, 2016, 22, 44-53.	7.0	193
14	Is there a need to redefine the upper normal limit of TSH?. European Journal of Endocrinology, 2006, 154, 633-637.	3.7	179
15	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	3.6	179
16	2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. European Thyroid Journal, 2019, 8, 227-245.	2.4	179
17	Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. European Journal of Endocrinology, 2005, 153, 651-659.	3.7	174
18	Total Thyroidectomy and Adjuvant Radioiodine Treatment Independently Decrease Locoregional Recurrence Risk in Childhood and Adolescent Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 2007, 48, 879-888.	5.0	169

#	Article	IF	Citations
19	B-Raf^{V600E}and thrombospondin-1 promote thyroid cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10649-10654.	7.1	164
20	Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocrine-Related Cancer, 2005, 12, 773-803.	3.1	160
21	Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Design, Development and Therapy, 2015, 9, 5075.	4.3	160
22	A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodineâ€refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer, 2015, 121, 2749-2756.	4.1	159
23	rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocrine-Related Cancer, 2005, 12, 49-64.	3.1	154
24	Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention. JAMA Oncology, 2017, 3, 1204.	7.1	149
25	Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 833-841.	6.4	141
26	Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncology, The, 2014, 15, 648-655.	10.7	137
27	Differentiation of the Sexually Dimorphic Nucleus in the Preoptic Area of the Rat Brain Is Inhibited by Postnatal Treatment with an Estrogen Antagonist. Neuroendocrinology, 1984, 38, 297-301.	2.5	136
28	Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma. Thyroid, 2014, 24, 232-240.	4.5	130
29	European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics. European Thyroid Journal, 2017, 6, 115-129.	2.4	127
30	GermlineNF1Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2784-2792.	3.6	126
31	European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid, 2019, 29, 7-26.	4.5	122
32	Heterogeneity of Thyroid Cancer. Pathobiology, 2018, 85, 117-129.	3.8	117
33	Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Molecular and Cellular Endocrinology, 2010, 322, 8-28.	3.2	114
34	A gene expression signature distinguishes normal tissues of sporadic and radiation-induced papillary thyroid carcinomas. British Journal of Cancer, 2012, 107, 994-1000.	6.4	111
35	Current genetic methodologies in the identification of disaster victims and in forensic analysis. Journal of Applied Genetics, 2012, 53, 41-60.	1.9	110
36	Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and qualityâ€ofâ€life assessments. Cancer, 2014, 120, 2694-2703.	4.1	106

#	Article	IF	Citations
37	Patient Ageâ€“Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 438-445.	1.6	102
38	Genome-Wide Association Study on Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1674-E1681.	3.6	101
39	Pre- and Postnatal Influence of an Estrogen Antagonist and an Androgen Antagonist on Differentiation of the Sexually Dimorphic Nucleus of the Preoptic Area in Male and Female Rats. Neuroendocrinology, 1986, 42, 443-448.	2.5	97
40	Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. European Journal of Endocrinology, 2004, 151, 539-548.	3.7	93
41	Estimation of Risk of Inherited Medullary Thyroid Carcinoma in Apparent Sporadic Patients. Journal of Clinical Oncology, 2001, 19, 1374-1380.	1.6	91
42	Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes and Endocrinology,the, 2019, 7, 213-220.	11.4	86
43	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3241-3250.	3.6	80
44	Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy. JAMA Network Open, 2019, 2, e198898.	5.9	80
45	Analysis options for high-throughput sequencing in miRNA expression profiling. BMC Research Notes, 2014, 7, 144.	1.4	75
46	SRGAP1Is a Candidate Gene for Papillary Thyroid Carcinoma Susceptibility. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E973-E980.	3.6	74
47	Gene Expression Analysis in Ovarian Cancer â€“ Faults and Hints from DNA Microarray Study. Frontiers in Oncology, 2014, 4, 6.	2.8	73
48	An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.. Journal of Clinical Oncology, 2012, 30, 5508-5508.	1.6	73
49	Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1077-1086.	6.4	71
50	A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocrine-Related Cancer, 2007, 14, 809-826.	3.1	67
51	Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. Molecular and Cellular Endocrinology, 2014, 388, 1-9.	3.2	66
52	Impact of SNPs on methylation readouts by Illumina Infinium HumanMethylation450 BeadChip Array: implications for comparative population studies. BMC Genomics, 2015, 16, 1003.	2.8	61
53	Gene signature of the post-Chernobyl papillary thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1267-1277.	6.4	61
54	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. Journal of the National Cancer Institute, 2018, 110, 362-370.	6.3	60

#	Article	IF	Citations
55	Association of CD40 Gene Polymorphism (C-1T) with Susceptibility and Phenotype of Graves' Disease. Thyroid, 2005, 15, 1119-1124.	4.5	59
56	BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 2787-2795.	1.6	58
57	Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. British Journal of Clinical Pharmacology, 2016, 81, 1124-1133.	2.4	55
58	Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi. Thyroid Research, 2010, 3, 9.	1.5	53
59	Perspectives and Limitations of Microarray-Based Gene Expression Profiling of Thyroid Tumors. Endocrine Reviews, 2007, 28, 322-338.	20.1	51
60	13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. Thyroid Research, 2009, 2, 8.	1.5	51
61	BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma. PLoS ONE, 2015, 10, e0143688.	2.5	49
62	NBL1 and anillin (ANLN) genes over-expression in pancreatic carcinoma.. Folia Histochemica Et Cytobiologica, 2009, 47, 249-55.	1.5	46
63	Przypadkowo wykryty guz nadnercza (incydentaloma) u dorosÅ‚ych â€" zasady postÄ™powania rekomendowane przez Polskie Towarzystwo Endokrynologiczne. Endokrynologia Polska, 2016, 67, 234-258.	1.0	46
64	Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival inÂanaplastic thyroid cancer. Surgery, 2012, 152, 1078-1087.	1.9	45
65	Association of NFKB1 â^'94ins/del ATTG promoter polymorphism with susceptibility to and phenotype of Graves' disease. Genes and Immunity, 2007, 8, 532-538.	4.1	43
66	Preventive medicine of von Hippelâ€“Lindau disease-associated pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 783-793.	3.1	42
67	Zalecenia ogÃ³lne dotyczÄ...ce postÄ™powania w nowotworach neuroendokrynnych ukÅ‚adu pokarmowego (rekomendowane przez PolskÄ... SieÄ‡ GuzÃ³w Neuroendokrynnych). Endokrynologia Polska, 2014, 64, 418-443.	1.0	42
68	Novel Genome-Wide Association Studyâ€“Based Candidate Loci for Differentiated Thyroid Cancer Risk. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2084-E2092.	3.6	41
69	BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. European Journal of Cancer, 2020, 124, 161-169.	2.8	41
70	Zalecenia ogÃ³lne dotyczÄ...ce postÄ™powania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych ukÅ‚adu pokarmowego (rekomendowane przez PolskÄ... SieÄ‡ GuzÃ³w) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 137	1.0	40
71	miRNAs with the Potential to Distinguish Follicular Thyroid Carcinomas from Benign Follicular Thyroid Tumors: Results of a Meta-analysis. Hormone and Metabolic Research, 2014, 46, 171-180.	1.5	39
72	Serotoninergic Influences on Sexual Differentiation of the Rat Brain. Progress in Brain Research, 1984, 61, 119-126.	1.4	38

#	Article	IF	Citations
73	Association between Age at Diagnosis of Graves' Disease and Variants in Genes Involved in Immune Response. PLoS ONE, 2013, 8, e59349.	2.5	38
74	Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival. Frontiers in Endocrinology, 2020, 11, 571421.	3.5	38
75	Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma. European Archives of Oto-Rhino-Laryngology, 2009, 266, 1501-1507.	1.6	37
76	Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients. International Journal of Molecular Sciences, 2018, 19, 2647.	4.1	37
77	Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18493-18498.	7.1	36
78	Somatic mutation profiling of follicular thyroid cancer by next generation sequencing. Molecular and Cellular Endocrinology, 2016, 433, 130-137.	3.2	36
79	BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3228-3238.	3.6	36
80	A two miRNA classifier differentiates follicular thyroid carcinomas from follicular thyroid adenomas. Molecular and Cellular Endocrinology, 2015, 399, 43-49.	3.2	35
81	Dynamic risk stratification in the follow-up of thyroid cancer: what is still to be discovered in 2017?. Endocrine-Related Cancer, 2017, 24, R387-R402.	3.1	35
82	Thyroid Stimulating Hormone Receptor (TSHR) Intron 1 Variants Are Major Risk Factors for Graves' Disease in Three European Caucasian Cohorts. PLoS ONE, 2010, 5, e15512.	2.5	35
83	Using SVD and SVM methods for selection, classification, clustering and modeling of DNA microarray data. Engineering Applications of Artificial Intelligence, 2004, 17, 417-427.	8.1	34
84	Meta- and Reanalysis of Gene Expression Profiles of Hot and Cold Thyroid Nodules and Papillary Thyroid Carcinoma for Gene Groups. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1934-1942.	3.6	34
85	Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?. International Journal of Molecular Sciences, 2017, 18, 1817.	4.1	34
86	Gene expression profile of human thyroid cancer in relation to its mutational status. Journal of Molecular Endocrinology, 2011, 47, R91-R103.	2.5	33
87	Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. Journal of Clinical Oncology, 2020, 38, 2773-2781.	1.6	33
88	Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours. International Journal of Molecular Sciences, 2017, 18, 1184.	4.1	32
89	Rekomendacje Polskich Towarzystw Naukowych â€žDiagnostyka i leczenie raka tarczycyâ€• Aktualizacja na rok 2018. Endokrynologia Polska, 2018, 69, 34-74.	1.0	32
90	The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors. PLoS ONE, 2015, 10, e0132821.	2.5	31

#	Article	IF	Citations
91	Diagnostyka i leczenie raka tarczycy. Endokrynologia Polska, 2016, 67, 74-145.	1.0	31
92	The prognostic value of tumor markers doubling time in medullary thyroid carcinoma - preliminary report. Thyroid Research, 2010, 3, 10.	1.5	30
93	Locus 1q21 Gene Expression Changes in Atopic Dermatitis Skin Lesions: Deregulation of Small Proline-Rich Region 1A. International Archives of Allergy and Immunology, 2010, 151, 28-37.	2.1	30
94	Sorafenib for the treatment of thyroid cancer: an updated review. Expert Opinion on Pharmacotherapy, 2015, 16, 573-583.	1.8	30
95	Use of Monoclonal Anti-EGFR Antibody in the Radioimmunotherapy of Malignant Gliomas in the Context of EGFR Expression in Grade III and IV Tumors. Hybridoma, 2006, 25, 125-132.	0.4	29
96	A registry-based study of thyroid paraganglioma: histological and genetic characteristics. Endocrine-Related Cancer, 2015, 22, 191-204.	3.1	29
97	Molecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffin-embedded tissues. BMC Medical Genomics, 2013, 6, 38.	1.5	28
98	Interaction of HLA-DRB1 Alleles with CTLA-4 in the Predisposition to Graves' Disease: The Impact of DRB1*07. Thyroid, 2006, 16, 447-453.	4.5	27
99	Two-miRNA classifiers differentiate mutation-negative follicular thyroid carcinomas and follicular thyroid adenomas in fine needle aspirations with high specificity. Endocrine, 2016, 54, 440-447.	2.3	27
100	Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. Expert Review of Clinical Pharmacology, 2016, 9, 69-79.	3.1	27
101	RET polymorphisms in codons 769 and 836 are not associated with predisposition to medullary thyroid carcinoma. Cancer Detection and Prevention, 2004, 28, 231-236.	2.1	26
102	EurEAs_Gplex â€"A new SNaPshot assay for continental population discrimination and gender identification. Forensic Science International: Genetics, 2016, 20, 89-100.	3.1	26
103	BRCA1-related gene signature in breast cancer the role of ER status and molecular type. Frontiers in Bioscience - Elite, 2011, E3, 125-136.	1.8	25
104	Gene Expression Profiles for Radiation-induced Thyroid Cancer. Clinical Oncology, 2011, 23, 282-288.	1.4	25
105	Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline.. Journal of Clinical Oncology, 2015, 33, 6012-6012.	1.6	25
106	CHANGES IN SERUM TSH LEVEL AFTER INTRAVENTRICULAR INJECTION OF VARIOUS NEUROMEDIATORS IN RATS. European Journal of Endocrinology, 1978, 87, 279-282.	3.7	24
107	A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).. Journal of Clinical Oncology, 2012, 30, 5591-5591.	1.6	24
108	OdrÃ³Å¼nienie brodawkowatego raka tarczycy od tkanki nienowotworowej w oparciu o profilowanie lipidÃ³w metodÄ... MALDI-MSI. Endokrynologia Polska, 2018, 69, 2-8.	1.0	24

#	Article	IF	Citations
109	Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk. Scientific Reports, 2015, 5, 8922.	3.3	23
110	Concentrations of Selected Adipokines, Interleukin-6, and Vitamin D in Patients with Papillary Thyroid Carcinoma in Respect to Thyroid Cancer Stages. International Journal of Endocrinology, 2018, 2018, 1-7.	1.5	23
111	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. Journal of Clinical Oncology, 2013, 31, 4-4.	1.6	23
112	Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells. Molecular Cancer, 2014, 13, 160.	19.2	22
113	Transcriptional profiles of pilocytic astrocytoma are related to their three different locations, but not to radiological tumor features. BMC Cancer, 2015, 15, 778.	2.6	22
114	Polskie rekomendacje diagnostyki i leczenia zrÃ³Å¼nicowanego raka tarczycy u dzieci. Endokrynologia Polska, 2016, 67, 628-642.	1.0	22
115	Postnatal treatment of rats with the Î²2-adrenergic agonist salbutanol influences the volume of the sexually dimorphic nucleus in the preoptic area. Brain Research, 1990, 516, 257-262.	2.2	20
116	Is there loss or qualitative changes in the expression of thyroid peroxidase protein in thyroid epithelial cancer?. British Journal of Cancer, 2001, 85, 875-880.	6.4	20
117	Association between Polymorphisms in the TSHR Gene and Graves' Orbitopathy. PLoS ONE, 2014, 9, e102653.	2.5	20
118	CiÄ...gÅ‚a stratyfikacja ryzyka w zrÃ³Å¼nicowanym raku tarczycy (DTC) â€" stymulowane stÄ™Å¼enie tyreoglobuliny (Tg) w surowicy, przed leczeniem uzupeÅ‚niajÄ...cym radiojodem (RAI), najwaÅ¼niejszym czynnikiem ryzyka nawrotu raka u pacjentÃ³w M0. Endokrynologia Polska, 2016, 67, 2-11.	1.0	20
119	Nowotwory neuroendokrynne Å¼oÅ‚Ä...dka i dwunastnicy z uwzglÄ™dnieniem gastrinoma (zasady postÄ™powania) Tj ETQq1 1 0.7	1.0	20
120	Nowotwory neuroendokrynne jelita grubego â€" zasady postÄ™powania (rekomendowane przez PolskÄ... SieÄ‡) Tj ETQq0 0 0 rgBT /Ov	1.0	20
121	Novel TGâ€FGFR1 and TRIM33â€NTRK1 transcript fusions in papillary thyroid carcinoma. Genes Chromosomes and Cancer, 2019, 58, 558-566.	2.8	19
122	Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego â€" zasady postÄ™powania (rekomendowane przez PolskÄ... SieÄ‡ GuzÃ³w Neuroendokrynnych). Endokrynologia Polska, 2017, 68, 223-236.	1.0	18
123	Influence of Neurotransmitters on Sexual Differentiation of Brain Structure and Function. Experimental and Clinical Endocrinology and Diabetes, 1991, 98, 99-109.	1.2	17
124	Molecular signature of cell cycle exit induced in human T lymphoblasts by IL-2 withdrawal. BMC Genomics, 2009, 10, 261.	2.8	17
125	Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response.. Journal of Clinical Oncology, 2012, 30, 5518-5518.	1.6	17
126	Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study. Endocrine Connections, 2020, 9, 489-497.	1.9	17

#	Article	IF	Citations
127	Diagnosis and treatment of thyroid cancer in adult patients â€" Recommendations of Polish Scientific Societies and the National Oncological Strategy. 2022 Update [Diagnostyka i leczenie raka tarczycy u chorych dorosÅ‚ych â€" Rekomendacje Polskich Towarzystw Naukowych oraz Narodowej Strategii Onkologicznej. Aktualizacja na rok 2022]. Endokrynologia Polska, 2022, 73, 173-300.	1.0	17
128	Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations. Scientific Reports, 2017, 7, 42074.	3.3	16
129	Advances in small molecule therapy for treating metastatic thyroid cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 1049-1060.	1.8	16
130	Genetic testing in inherited endocrine disorders: joint position paper of the European reference network on rare endocrine conditions (Endo-ERN). Orphanet Journal of Rare Diseases, 2020, 15, 144.	2.7	15
131	Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers â€" the role of Ct serum level. Thyroid Research, 2013, 6, S9.	1.5	14
132	Drug safety evaluation of lenvatinib for thyroid cancer. Expert Opinion on Drug Safety, 2015, 14, 1935-1943.	2.4	14
133	Gender-dependent and age-of-onset-specific association of the rs11675434 single-nucleotide polymorphism near TPO with susceptibility to Gravesâ€™ ophthalmopathy. Journal of Human Genetics, 2017, 62, 373-377.	2.3	14
134	Paediatricâ€onset and adultâ€onset Graves' disease share multiple genetic risk factors. Clinical Endocrinology, 2019, 90, 320-327.	2.4	14
135	Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial.. Journal of Clinical Oncology, 2014, 32, 6060-6060.	1.6	14
136	Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer. European Journal of Endocrinology, 2015, 173, 873-881.	3.7	13
137	Managing tyrosine kinase inhibitors side effects in thyroid cancer. Expert Review of Endocrinology and Metabolism, 2017, 12, 117-127.	2.4	13
138	TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma. Cancers, 2020, 12, 1597.	3.7	13
139	CzÄ™stoÅ›Ä‡ wystÄ™powania mutacji somatycznych RAS w raku rdzeniastym tarczycy â€" analiza populacji polskiej. Endokrynologia Polska, 2015, 66, 121-125.	1.0	13
140	Current status of the prognostic molecular markers in medullary thyroid carcinoma. Endocrine Connections, 2020, 9, R251-R263.	1.9	13
141	Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide. Wspolczesna Onkologia, 2017, 2, 115-122.	1.4	12
142	European perspective on the use of molecular tests in the diagnosis and therapy of thyroid neoplasms. Gland Surgery, 2020, 9, S69-S76.	1.1	12
143	Rola medycyny nuklearnej w diagnostyce rÃ³Å¼nicowej Å›ledzion dodatkowych u chorych po splenektomii. Polski Przeglad Radiologii I Medycyny Nuklearnej, 2012, 77, 68-71.	1.0	12
144	Prevalence of RAS Point Mutations in Papillary Thyroid Carcinoma; A Novel Mutation at Codon 31 of K-RAS. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 594-599.	1.2	11

#	Article	IF	Citations
145	Differences in Gene-Gene Interactions in Gravesâ€™ Disease Patients Stratified by Age of Onset. PLoS ONE, 2016, 11, e0150307.	2.5	11
146	Efficacy of lenvatinib in treating thyroid cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 1683-1691.	1.8	11
147	Atypical presentation of invasive pulmonary aspergillosis in a liver transplant recipient. Annals of Transplantation, 2013, 18, 238-242.	0.9	11
148	Terapia radioizotopowa 131-MIBG zÅ‚oÅ›liwych guzÃ³w chromochÅ‚onnych i przyzwojakÃ³w â€" badanie jednooÅ›rodkowe. Endokrynologia Polska, 2018, 69, 246-251.	1.0	11
149	Postnatal treatment of rats with adrenergic receptor agonists or antagonists influences differentiation of sexual behavior. Hormones and Behavior, 1987, 21, 478-492.	2.1	10
150	Application of Bayesian networks for inferring causeâ€“effect relations from gene expression profiles of cancer versus normal cells. Mathematical Biosciences, 2007, 209, 528-546.	1.9	10
151	The role of FDG-PET in localization of recurrent lesions of differentiated thyroid cancer (DTC) in patients with asymptomatic hyperthyroglobulinemia in a real clinical practice. European Journal of Endocrinology, 2016, 175, 379-385.	3.7	10
152	Postoperative Radioiodine Treatment within 9ÂMonths from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma. Nuclear Medicine and Molecular Imaging, 2019, 53, 320-327.	1.0	10
153	Original article Expression of genes FOLR1, BAG1 and LAPTM4B in functioning and non-functioning pituitary adenomas. Folia Neuropathologica, 2012, 3, 277-286.	1.2	9
154	Novel therapies for thyroid cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 2641-2652.	1.8	9
155	A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60â€‰mg Per Day Compared with the Cabozantinib Capsule at 140â€‰mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. Thyroid, 2022, 32, 515-524.	4.5	9
156	Gene expression signatures and ex vivo drug sensitivity profiles in children with acute lymphoblastic leukemia. Journal of Applied Genetics, 2012, 53, 83-91.	1.9	8
157	The Association of SNPs Located in the CDKN2B-AS1 and LPA Genes With Carotid Artery Stenosis and Atherogenic Stroke. Frontiers in Neurology, 2019, 10, 1170.	2.4	8
158	Impact of the Tumor Microenvironment on the Gene Expression Profile in Papillary Thyroid Cancer. Pathobiology, 2020, 87, 143-154.	3.8	8
159	Terapia nadczynnoÅ›ci tarczycy jodem promieniotwÃ³rczym jest bezpieczna u chorych na chorobÄ™ Gravesa i Basedowa z orbitopatiÄ... â€" badanie prospektywne. Endokrynologia Polska, 2014, 65, 40-45.	1.0	8
160	Papillary Thyroid Carcinoma in a Boy with Familial Tuberous Sclerosis Complex Attributable to a TSC2 Deletionâ€"A Case Report. Current Oncology, 2017, 24, 423-428.	2.2	7
161	A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotypeâ€“Phenotype Correlations. Frontiers in Endocrinology, 2021, 12, 681013.	3.5	7
162	Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy. Folia Histochemica Et Cytobiologica, 2017, 54, 202-209.	1.5	7

#	Article	IF	Citations
163	131I INTERNAL CONTAMINATION AND COMMITTED DOSE ASSESSMENT AMONG NUCLEAR MEDICINE MEDICAL PERSONNEL. Radiation Protection Dosimetry, 2018, 179, 275-281.	0.8	6
164	Wiek zachorowania i pÅ‚eÄ‡ jako czynniki modyfikujÄ...ce zwiÄ...zek polimorfizmÃ³w zlokalizowanych na chromosomie 9q22 i 14q13 z rakiem brodawkowatym tarczycy. Endokrynologia Polska, 2017, 68, 283-289.	1.0	6
165	Multiple endocrine neoplasia type 1 in Poland: a two-centre experience. Endokrynologia Polska, 2019, 70, 385-391.	1.0	6
166	In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3841-3851.	6.4	6
167	Adrenergic Influences on Sexual Differentiation of the Rat Brain. Frontiers of Neurology and Neuroscience, 1986, 12, 191-196.	2.8	5
168	Postnatal Treatment of Rats with Beta-adrenergic Agonists or Antagonists Influences Differentiation	1.2	5
169	Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinomaâ€"Do They Exist?. International Journal of Molecular Sciences, 2020, 21, 4629.	4.1	5
170	Obraz kliniczny guzÃ³w chromochÅ‚onnych u nosicieli mutacji protoonkogenu RET â€" badanie jednooÅ›rodkowe. Endokrynologia Polska, 2016, 67, 54-58.	1.0	5
171	Endocrine complications of cancer immunotherapy. Endokrynologia Polska, 2018, 69, 722-733.	1.0	5
172	Immunoreactive calcitonin content in foetal thyroid glands and in placentae of rats. European Journal of Endocrinology, 1984, 105, 567-570.	3.7	4
173	Clinical utility gene card for: multiple endocrine neoplasia type 2. European Journal of Human Genetics, 2012, 20, 3-3.	2.8	4
174	Presentation of points of general discussion and voting among the speakers of the European Thyroid Association-Cancer Research Network (ETA-CRN) meeting in Lisbon, 2009, entitled â€Ł European comments to ATA medullary thyroid cancer guidelinesâ€• Thyroid Research, 2013, 6, S11.	1.5	4
175	LanroNET, aÂnon-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors â€" results of interim analysis. Wspolczesna Onkologia, 2014, 6, 442-447.	1.4	4
176	Lenvatinib for the treatment of radioiodine-refractory follicular and papillary thyroid cancer. Expert Opinion on Orphan Drugs, 2014, 2, 1331-1340.	0.8	4
177	Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer. Annals of Nuclear Medicine, 2021, 35, 1214-1222.	2.2	4
178	Fosbretabulin tromethamine in the treatment of thyroid cancer. Expert Opinion on Orphan Drugs, 2016, 4, 555-561.	0.8	3
179	Transcriptomic population markers for human population discrimination. BMC Genetics, 2018, 19, 54.	2.7	3
180	The role of postoperative adjuvant radiotherapy in local recurrence risk in medullary thyroid carcinoma. Endocrine Connections, 2020, 9, 1-8.	1.9	3

#	Article	IF	Citations
181	Unsupervised analysis of follicular thyroid tumours transcriptome by oligonucleotide microarray gene expression profiling. Endokrynologia Polska, 2013, 64, 328-334.	1.0	3
182	Klasyfikacja molekularna gruczolakÃ³w przysadki: w poszukiwaniu kryteriÃ³w przydatnych do badaÅ„ wysokoprzepustowych. Endokrynologia Polska, 2016, 67, 148-156.	1.0	3
183	Positive resources: feeling of hope and life satisfaction in a group of patients treated in childhood because of differentiated thyroid gland cancer. Wspolczesna Onkologia, 2010, 5, 316-320.	1.4	2
184	Hepatocytes Response to Interferon Alpha Levels Recorded After Liver Resection. Journal of Interferon and Cytokine Research, 2014, 34, 90-99.	1.2	2
185	Heterogeneity of the Clinical Presentation of the MEN1 LRG_509 c.781C>T (p.Leu261Phe) Variant Within a Three-Generation Family. Genes, 2021, 12, 512.	2.4	2
186	Stereotactic radiotherapy is a useful treatment option for patients with medullary thyroid cancer. BMC Endocrine Disorders, 2021, 21, 160.	2.2	2
187	Definitive treatment of Gravesâ€™ disease in children and adolescents. Endokrynologia Polska, 2021, 72, 661-665.	1.0	2
188	Introduction to European comments on â€œMedullary Thyroid Cancer: management guidelines of the American Thyroid Associationâ€• Thyroid Research, 2013, 6, S1.	1.5	1
189	Important considerations when choosing pharmacotherapy for Gravesâ€™ disease in children. Expert Opinion on Pharmacotherapy, 2019, 20, 1675-1677.	1.8	1
190	Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma â€“ Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015. Frontiers in Endocrinology, 2021, 12, 718833.	3.5	1
191	Thyroid and Irradiation. , 2018, , 539-544.		1
192	An internistâ€™s approach to cancer diseases based on the model of thyroid cancer treated with tyrosine kinase inhibitors. Polish Archives of Internal Medicine, 2016, 126, 925-928.	0.4	1
193	Emerging multikinase inhibitors for the treatment of differentiated thyroid cancer: whom to treat?. Translational Cancer Research, 2016, 5, S1340-S1344.	1.0	1
194	Surgical approach to differentiated thyroid cancers (DTC) in children [Specyfika leczenia chirurgicznego zrÃ³Å¼nicowanych rakÃ³w tarczycy (ZRT) u dzieci]. Endokrynologia Polska, 2019, 70, 357-366.	1.0	1
195	Laparoscopic cortical-sparing adrenal surgery in pheochromocytomas associated with hereditary neoplasia syndromes. Endokrynologia Polska, 2020, 71, 518-523.	1.0	1
196	Ocena bezpieczeÅ„stwa i efektywnoÅ›Ä‡ jabÅ‚czanu sunitynibu w przerzutowych guzach neuroendokrynnych trzustki (NEN G1/G2) w zależnoÅ›ci od liczby i rodzaju wczeÅ›niejszych linii terapeutycznych â€” doniesienie wstÄ™pne. Endokrynologia Polska, 2015, 65, 472-478.	1.0	1
197	The role of thyroid sonographic malignancy risk features when the fine needle aspiration biopsy result is indeterminate. Endokrynologia Polska, 2022, 73, 316-324.	1.0	1
198	Consenso europeo para el tratamiento de los pacientes con carcinoma tiroideo diferenciado del epitelio folicular. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2007, 54, 390.e1-390.e16.	0.8	0

#	Article	IF	Citations
199	Differences in the expression profiles of normal contralateral tissues of papillary thyroid cancer patients exposed and not exposed to the Chernobyl fallout. Medecine Nucleaire, 2011, 35, 327-328.	0.2	0
200	Reply to J.-F. Chatal et al. Journal of Clinical Oncology, 2012, 30, 2166-2167.	1.6	0
201	Gene Expression Analysis by DNA Microarray in Papillary and Follicular Differentiated Thyroid Cancer. Medical Radiology, 2012, , 233-244.	0.1	0
202	Profil ekspresji genÃ³w w raku pÅ‚askonabÅ‚onkowym krtani in vivo przy uÅ¼yciu mikromacierzy oligonukleotydowych wysokiej gÄ™stoÅ›ci. , 2013, 2, 63-69.		0
203	Radioactive Iodine. , 2018, , 688-692.		0
204	Medullary Carcinoma. Endocrinology, 2018, , 589-627.	0.1	0
205	Recent advances in precision medicine for the treatment of medullary thyroid cancer. Expert Review of Precision Medicine and Drug Development, 2021, 6, 307-315.	0.7	0
206	Adjuvant Treatment and Follow Up of Differentiated Thyroid Cancer. Head and Neck Cancer Clinics, 2012, , 125-143.	0.0	0
207	Preoperative Endocrine Management of Differentiated Thyroid Cancer. Head and Neck Cancer Clinics, 2012, , 45-53.	0.0	0
208	Multikinase Inhibitors for the Treatment of Progressive, Metastatic Medullary Thyroid Cancer â€“ An Evolving Paradigm. European Endocrinology, 2014, 10, 145.	1.5	0
209	Medullary Carcinoma. Endocrinology, 2018, , 1-39.	0.1	0
210	Current surgical management in RET mutation carriers [Aktualne postÄ™powanie chirurgiczne u nosicieli mutacji proto-onkogenu RET]. Endokrynologia Polska, 2019, 70, 367-379.	1.0	0
211	Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer â€“ a prospective comparison of long-term outcomes. Archives of Medical Science, 2020, , .	0.9	0